Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics in the United States, Europe, and Canada. Its lead product candidate is obeticholic acid (OCA), a bile acid analog, which has a structure based on a naturally occurring human bile acid that selectively binds to and activates the farnesoid X receptor (FXR). The company is developing OCA to treat various non-viral progressive liver diseases, such as nonalcoholic steatohepatitis (NASH), primary sclerosing cholangitis, and biliary atresia. It also provides OCA under the Ocaliva brand name for the treatment of primary biliary cholangitis (PBC). In addition, the company is developing INT-767, an orally administered dual FXR and TGR5 agonist, a second dedicated bile acid receptor that has completed a Phase 1 clinical trial; and INT-777, an orally administered TGR5 agonist, which completed preclinical studies for the treatment of type 2 diabetes, associated metabolic disorders, and other gastrointestinal indications. Intercept Pharmaceuticals, Inc. has a license agreement with Sumitomo Dainippon Pharma Co. Ltd. for the research, development, and commercialization of OCA as a therapeutic for the treatment of PBC and NASH in Japan and China. The company was founded in 2002 and is headquartered in New York, New York.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Phone646-747-1000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$179.80 million
Profitability
Miscellaneous
Employees483
Next Earnings Date5/14/2019 (Estimated)
OptionableOptionable
Intercept Pharmaceuticals (NASDAQ:ICPT) Frequently Asked Questions
What is Intercept Pharmaceuticals' stock symbol?
Intercept Pharmaceuticals trades on the NASDAQ under the ticker symbol "ICPT."
How were Intercept Pharmaceuticals' earnings last quarter?
Intercept Pharmaceuticals Inc (NASDAQ:ICPT) posted its quarterly earnings results on Thursday, February, 28th. The biopharmaceutical company reported ($2.97) EPS for the quarter, missing the consensus estimate of ($2.42) by $0.55. The biopharmaceutical company had revenue of $53.30 million for the quarter, compared to analysts' expectations of $52.53 million. Intercept Pharmaceuticals had a negative return on equity of 592.58% and a negative net margin of 172.39%. The company's revenue was up 41.4% compared to the same quarter last year. During the same period last year, the business posted ($4.43) earnings per share. View Intercept Pharmaceuticals' Earnings History.
When is Intercept Pharmaceuticals' next earnings date?
What price target have analysts set for ICPT?
21 brokerages have issued 12 month target prices for Intercept Pharmaceuticals' shares. Their predictions range from $68.00 to $251.00. On average, they expect Intercept Pharmaceuticals' stock price to reach $147.10 in the next twelve months. This suggests a possible upside of 27.7% from the stock's current price. View Analyst Price Targets for Intercept Pharmaceuticals.
What is the consensus analysts' recommendation for Intercept Pharmaceuticals?
21 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Intercept Pharmaceuticals in the last year. There are currently 2 sell ratings, 4 hold ratings and 15 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Intercept Pharmaceuticals.
What are Wall Street analysts saying about Intercept Pharmaceuticals stock?
Here are some recent quotes from research analysts about Intercept Pharmaceuticals stock:
- 1. Cantor Fitzgerald analysts commented, ". We reiterate our Overweight rating and $170 PT. Positive Ph3 data on fibrosis de-risk this binary readout. Intercept announced this morning that the 25mg dose hit on one of the key endpoints, which is a one point change in fibrosis stage (OCA 23.1%, placebo 11.9%, p-value=0.0002). They saw a numerical trend on NASH resolution in the 25mg. Although this endpoint did not hit (25mg p-value=0.1268), we believe that the data profile for OCA will support approval; fibrosis is relevant for potential liver outcomes. Since there was a p-value of 0.0013 when F1 co-morbidities were added, we are interested to see more analysis around NASH resolution." (2/19/2019)
- 2. According to Zacks Investment Research, "Intercept got a significant boost with the approval of Ocaliva for the treatment of PBC. Although sales had earlier taken a hit due to the safety issues regarding Ocaliva, management’s efforts to increase awareness about the updated level and promote Ocaliva, thereafter, is reaping results. While we are pleased with the approval of Ocaliva, the company’s dependence on a single product for growth has its risks. Any negative news related to Ocaliva would adversely impact Intercept and its growth prospects. The lack of other candidates in the pipeline is concerning. Nevertheless, the company is looking to expand the drug’s label in the promising NASH and PSC space. The phase III NASH program includes the REGENERATE trial among patients with advanced liver fibrosis and the REVERSE trial among patients with compensated cirrhosis. Shares have outperformed the industry in the last six months." (2/15/2019)
Has Intercept Pharmaceuticals been receiving favorable news coverage?
News headlines about ICPT stock have been trending neutral this week, InfoTrie Sentiment Analysis reports. The research group rates the sentiment of media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Intercept Pharmaceuticals earned a media sentiment score of 0.3 on InfoTrie's scale. They also assigned news headlines about the biopharmaceutical company a news buzz of 3.0 out of 10, meaning that recent media coverage is unlikely to have an effect on the company's share price in the near term.
Are investors shorting Intercept Pharmaceuticals?
Intercept Pharmaceuticals saw a increase in short interest in February. As of February 28th, there was short interest totalling 4,902,660 shares, an increase of 51.6% from the February 15th total of 3,232,927 shares. Based on an average trading volume of 3,174,024 shares, the days-to-cover ratio is currently 1.5 days. Currently, 22.0% of the shares of the stock are short sold. View Intercept Pharmaceuticals' Current Options Chain.
Who are some of Intercept Pharmaceuticals' key competitors?
Some companies that are related to Intercept Pharmaceuticals include GRIFOLS S A/S (GRFS), Ionis Pharmaceuticals (IONS), Genmab A/S (GNMSF), Alnylam Pharmaceuticals (ALNY), Bausch Health Companies (BHC), Sarepta Therapeutics (SRPT), Beigene (BGNE), Jazz Pharmaceuticals (JAZZ), Loxo Oncology (LOXO), SAGE Therapeutics (SAGE), Dr.Reddy's Laboratories (RDY), Perrigo (PRGO), Marina Biotech (MRNA), Catalent (CTLT) and Amarin (AMRN).
What other stocks do shareholders of Intercept Pharmaceuticals own?
Who are Intercept Pharmaceuticals' key executives?
Intercept Pharmaceuticals' management team includes the folowing people:
- Dr. Mark Pruzanski, Founder, CEO, Pres & Director (Age 51)
- Mr. Sandip S. Kapadia, CFO, Treasurer & Principal Accounting Officer (Age 49)
- Mr. Jerome B. Durso, Chief Operating Officer (Age 51)
- Mr. David Ford, Chief HR Officer (Age 50)
- Dr. David Shapiro, Chief Medical Officer (Age 65)
Who are Intercept Pharmaceuticals' major shareholders?
Intercept Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional investors include FMR LLC (15.00%), First Trust Advisors LP (3.31%), BB Biotech AG (1.94%), Two Sigma Investments LP (1.05%), Eagle Asset Management Inc. (0.96%) and Norges Bank (0.95%). Company insiders that own Intercept Pharmaceuticals stock include Christian Weyer, Daniel G Welch, David Shapiro, Francesco Micheli, Keith Michael Gottesdiener, Lisa Bright, Mark Pruzanski, Rachel Mcminn, Richard J Kim, Sandip Kapadia, SPA Genextra and Srinivas Akkaraju. View Institutional Ownership Trends for Intercept Pharmaceuticals.
Which institutional investors are selling Intercept Pharmaceuticals stock?
ICPT stock was sold by a variety of institutional investors in the last quarter, including First Trust Advisors LP, Elk Creek Partners LLC, Biondo Investment Advisors LLC, South Dakota Investment Council, Pinnacle Associates Ltd., Millennium Management LLC, MetLife Investment Advisors LLC and Virtus ETF Advisers LLC. Company insiders that have sold Intercept Pharmaceuticals company stock in the last year include Christian Weyer, David Shapiro, Lisa Bright, Mark Pruzanski, SPA Genextra and Srinivas Akkaraju. View Insider Buying and Selling for Intercept Pharmaceuticals.
Which institutional investors are buying Intercept Pharmaceuticals stock?
ICPT stock was purchased by a variety of institutional investors in the last quarter, including Eagle Asset Management Inc., Norges Bank, Two Sigma Investments LP, Sofinnova Investments Inc., Two Sigma Advisers LP, BB Biotech AG, Canada Pension Plan Investment Board and Assenagon Asset Management S.A.. Company insiders that have bought Intercept Pharmaceuticals stock in the last two years include Francesco Micheli, Keith Michael Gottesdiener and Mark Pruzanski. View Insider Buying and Selling for Intercept Pharmaceuticals.
How do I buy shares of Intercept Pharmaceuticals?
Shares of ICPT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Intercept Pharmaceuticals' stock price today?
One share of ICPT stock can currently be purchased for approximately $115.15.
How big of a company is Intercept Pharmaceuticals?
Intercept Pharmaceuticals has a market capitalization of $3.42 billion and generates $179.80 million in revenue each year. The biopharmaceutical company earns $-309,240,000.00 in net income (profit) each year or ($10.86) on an earnings per share basis. Intercept Pharmaceuticals employs 483 workers across the globe.
What is Intercept Pharmaceuticals' official website?
How can I contact Intercept Pharmaceuticals?
Intercept Pharmaceuticals' mailing address is 10 Hudson Yards 37th FL, New York NY, 10001. The biopharmaceutical company can be reached via phone at 646-747-1000 or via email at [email protected]
MarketBeat Community Rating for Intercept Pharmaceuticals (NASDAQ ICPT)
MarketBeat's community ratings are surveys of what our community members think about Intercept Pharmaceuticals and other stocks. Vote "Outperform" if you believe ICPT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ICPT will underperform the S&P 500 over the long term. You may vote once every thirty days.
